Adicet Bio, Inc. (ACET) has been beaten down lately with too much selling pressure. While the stock has lost 16.4% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator ...

Adicet Bio (NASDAQ:ACET) just reported results for the fourth quarter of 2023.Adicet Bio reported earnings per share of -69 cents. This met the analyst estimate for EPS of -69 cents.The company did not report any revenue for the quarter.InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38359 Adicet Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 81-3305277 (State or other jurisdiction of (I.R.S ...

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2023. “We are excited to explore the potential of our gamma delta T cell platform in autoimmune diseases following the FDA’s IND clearance of ADI-001 in lupus nephritis,” said ...

High-risk stocks could potentially turn the tables for investors willing to stomach the risk. Moreover, as the Nasdaq Composite hit a fresh high last Friday, ahead of its 2021 peak, the market’s appetite for risk continues to grow. The S&P 500’s ascent to 5,137 marks its 15th record closure for the year, underscoring the eagerness among investors to embrace riskier ventures. Hence, this climate is ripe for high-risk stocks that could pay off, provided they are grounded on a robust foundation and present ste ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Adicet Bio, Inc. (ACET) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Adicet Bio, Inc. is a member of the Medical sector. This group includes 1065 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank considers 16 different groups, me ...

Penny stocks are heating up as the S&P 500 hits new highs, signaling opportunity. With the S&P 500 posting new highs multiple times in the past few months and prospects of lower interest rates, the stage is set for potentially lucrative penny stock investments. However, the stocks in the article stand to benefit not just from favorable macroeconomic trends but also from company-specific catalysts. Moreover, given the uncertainty surrounding rate cuts, it is imperative for investors looking to capitalize on ...

While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum.This is a good time to remind you of all the reasons you shouldn’t buy biotech penny stocks. The first reason centers on the last two words. While many of these companies may claim advanced clinical data and whatnot, the reality is that many if not most players in this field will fail. That’ ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Adicet Bio, Inc. (ACET) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Adicet Bio, Inc. is one of 1072 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, ...

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference being held from February 7-8, 2024 in New York. Details of the event are as follows: Date: Thursday, Februar ...